Print

Print


from Viartis

19th August 2009 - New research
THE LOSS OF SEX DRIVE IN PARKINSON'S DISEASE
The journal of sexual medicine [2009] 6 (4) : 1024-1031 (Kummer A, Cardoso 
F, Teixeira AL) Complete abstract

Sexual dysfunction is a frequent but neglected problem in Parkinson's 
Disease, as muscular problems are usually seen as the characteristic 
symptoms. However, nearly two thirds (65.6%) of people with Parkinson's 
Disease have been found to suffer a loss of sex drive. Over 42% of those men 
with Parkinson's Disease also complained of erectile dysfunction. Ageing, 
female gender, lower education, and depression were most associated with 
decreased sexual desire. Decreased interest in sex was not associated with 
antidepressants. The neurological features that were most associated with a 
greater loss of sex drive were predominance of motor symptoms on the left 
side of the body, autonomic dysfunction, and severer Parkinson's Disease. In 
order to refer to this article on its own click here.

16th August 2009 - New report
A FUTURE REPLACEMENT FOR SINEMET
According to a new report, Depomed are developing a new drug called DM-1992 
that could outperform Sinemet in the treatment of Parkinson's Disease. For 
their report click here. The details are on page 20. Just like Sinemet, 
DM-1992 is a combination of L-dopa and carbidopa, which prevents the 
breakdown of L-dopa.  DM-1992 also includes AcuForm, which makes use of the 
properties of certain polymers. These polymers have long been used to 
"fluff" ice cream and are safe to use. For more information go to Depomed. 
Upon entering the stomach an AcuForm coated pill expands and is retained in 
the stomach for up to 8 hours. This helps to deliver a drug like Sinemet 
over a longer period of time. Depomed's formulation was able to extend the 
therapeutic duration of L-dopa to nine hours, compared to Sinemet CR's seven 
hours. The time to reach peak blood levels was extended to four hours 
compared to 2 hours for Sinemet CR. These advantages could enable a decrease 
in the dosage of L-dopa, and the ridding of side effects such as nausea and 
dyskinesia. In order to refer to this article on its own click here.

Rayilyn Brown
Director AZNPF
Arizona Chapter National Parkinson Foundation
[log in to unmask] 

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn